Conditions | Www.childrenshospital.org

-



von willebrand disease during pregnancy :: Article Creator

Von Willebrand Disease News, Research And Latest Updates

Keep abreast with the latest news related to von Willebrand Disease there are 388 news items on von Willebrand Disease that covers updates, breakthroughs and in-depth reports.

We provide you with a free downloadable secure widget for your website to carry news related to von Willebrand Disease.


Von Willebrand Factor Antigen

Primary Name Von Willebrand Factor Antigen Contraction VWF Ag UAB Procedure Number 2500390 CPT Code 85246 Specimen Collect one (1) blue-stopper tube (3.2% sodium citrate), filled to specified volume. Do not underfill or overfill. Specimen Management Centrifuge blue-stopper tube within one (1) hour of collection, separate plasma and test or quick-freeze at -70°C. Specimen Accepted Daily including weekends Test Performed Call Lab for Information Available Stat? No. Description The von Willebrand factor antigen assay is used to diagnose von Willebrand disease as it measures plasma von Willebrand factor concentration. When used in combination with the ristocetin cofactor test, the antigen test helps distinguish von Willebrand disease types 1 and 2. Reference Interval 50-150% Follow-up Test *The von Willebrand factor antigen test is usually run together with the ristocetin cofactor test and the factor VIII activity assay, forming the von Willebrand disease profile. Associated With Bleeding disorders Associated With Von Willebrand disease                © Copyright by the University of Alabama at Birmingham

Who Should Not Take Von Willebrand Factor (recombinant) Intravenous?

The following conditions are contraindicated with this drug. Check with your physician if you have any of the following:

  • obstruction of a blood vessel by a blood clot

    • Search Drugs Related Drugs

    Select a condition to view a list of medication options

    Drug Survey

    Are you currently using Von Willebrand Factor (recombinant) Intravenous?

    This survey is being conducted by the WebMD marketing sciences department.

    Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

    CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.





    Comments

    Post a Comment

    Popular posts from this blog

    Well-liked Medicare plan vs. higher-ranked providers - ChicagoNow

    -
    Image
    Medicare Open Enrollment ends December 7. The easy choice is to stay with all-in-one Medicare Advantage instead of switching to Traditional Medicare plus a supplement and drug plan. The hard one is whether to switch between Medicare Advantage plans, from a well-liked one to one accepted at a so-called top-10 hospital. Humana Gold Plus, a Medicare Advantage HMO, has served me well for five years. Hearing aids cost me only $10 after its $2,000 allowance. Routine doctor and dentist appointments and my medication cost nothing. But Humana Gold Plus is not accepted by Northwestern Memorial Hospital, the nearby hospital that US News & World Report ranks as the tenth best in the country, or by Northwestern Medicine physicians. My primary care physician is in an Advocate Medical Group. If I were hospitalized, it would be at Advocate Illinois Masonic Medical Center. If I had a serious illness, I’d see specialists in Advocate’s network. Illinois Masonic is not a second-rate hospital, and...
    Read more

    Minnesota veterans blame 3M's 'defective' ear plugs for hearing damage - KSTP

    -
    Image
    3M did not admit any wrongdoing as part of that settlement. Read 3M's full statement on the ear plugs here. "We deny this product was defectively designed," a company spokesperson said in a statement to 5 INVESTIGATES, adding they will "defend against the allegations in these lawsuits." More than 630 lawsuits have been filed and will be heard in a federal court in Florida. An attorney involved with the multi-district litigation says roughly 30 have been filed by veterans who live in Minnesota. Constant ringing Sarah Kay Carlson, an Army veteran from St. Paul, filed her lawsuit in April, claiming 3M exposed her and thousands of other Marines and soldiers to "extremely dangerous and disabling noise." 3M Earplug Complaint (Sarah Kay Carlson) Ramsey County (Filed) (PDF) 3M Earplug Complaint (Sarah Kay Carlson) Ramsey County (Filed) (Text) Carlson, who was deployed as part of Operation Iraqi Freedom in the late 2000s, provided security to convoys t...
    Read more

    Sickle Cell Disease (SCD): Practice Essentials, Background, Genetics

    -
    Image
    hemophilia c factor 11 :: Article Creator Regeneron Reports Fourth Quarter And Full Year 2023 Financial And Operating Results Fourth quarter 2023 revenues increased 1% to $3.43 billion versus fourth quarter 2022; excluding RonapreveTM(a)(b), revenuesincreased 14% Full year 2023 revenues increased 8% to $13.12 billion versus full year 2022;excluding Ronapreve(a), revenuesincreased 12% Fourth quarter 2023 Dupixent®global net sales(recorded by Sanofi) increased 31% to $3.22 billion versus fourth quarter 2022; full year 2023 Dupixent global net sales increased 33% to $11.59 billion versus 2022 Fourth quarter 2023 U.S. Net sales for EYLEA®HD and EYLEA®were $1.46 billion, including $123 million from EYLEA HD; full year 2023 U.S. Net sales for EYLEA HD and EYLEA were $5.89 billion, including $166 million from EYLEA HD following its August 2023 FDA approval Fourth quarter 2023 Libtayo®global n...
    Read more